alirocumab Praluent
Selected indexed studies
- Alirocumab (Praluent®). (, 1994) [PMID:35951828]
- Alirocumab (Praluent®). (, 1994) [PMID:35951829]
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. (JAMA, 2022) [PMID:35368058]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Effect of Alirocumab Added to High-Intensity Statin Therapy on Coronary Atherosclerosis in Patients With Acute Myocardial Infarction: The PACMAN-AMI Randomized Clinical Trial. (2022) pubmed
- Alirocumab in Pediatric Patients With Heterozygous Familial Hypercholesterolemia: A Randomized Clinical Trial. (2024) pubmed
- Effect of Alirocumab on Lipoprotein(a) and Cardiovascular Risk After Acute Coronary Syndrome. (2020) pubmed
- Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. (2015) pubmed
- Alirocumab (Praluent®). (1994) pubmed
- Alirocumab (Praluent®). (1994) pubmed
- Alirocumab (Praluent) to lower LDL-Cholesterol. (2015) pubmed
- Alirocumab (Praluent) for Treatment of Hyperlipidemia. (2016) pubmed
- Alirocumab. (2006) pubmed
- PCSK9 Inhibitors: Mechanism of Action, Efficacy, and Safety. (2018) pubmed